Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy
versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram
negative infections. The investigators intend to evaluate if this synergistic drug regimen
correlates with improved outcomes against gram-negative infections in critically ill patients
including: better clinical resolution, reduced length of stay at hospital, reduced length of
stay at the intensive care unit, and less recurrence of infection.